Bellevue Group’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-4,839,779
| Closed | -$7.99M | – | 155 |
|
|
2024
Q4 | $7.99M | Hold |
4,839,779
| – | – | 0.15% | 85 |
|
|
2024
Q3 | $16.9M | Hold |
4,839,779
| – | – | 0.27% | 77 |
|
|
2024
Q2 | $15.9M | Hold |
4,839,779
| – | – | 0.26% | 85 |
|
|
2024
Q1 | $35.5M | Sell |
4,839,779
-11,800
| -0.2% | -$86.6K | 0.54% | 59 |
|
|
2023
Q4 | $18.1M | Hold |
4,851,579
| – | – | 0.28% | 78 |
|
|
2023
Q3 | $10.3M | Sell |
4,851,579
-4,200
| -0.1% | -$8.9K | 0.17% | 90 |
|
|
2023
Q2 | $23.1M | Hold |
4,855,779
| – | – | 0.33% | 69 |
|
|
2023
Q1 | $27.7M | Sell |
4,855,779
-5,500
| -0.1% | -$31.4K | 0.4% | 66 |
|
|
2022
Q4 | $49.1M | Buy |
4,861,279
+1,115,193
| +30% | +$11.3M | 0.65% | 51 |
|
|
2022
Q3 | $84M | Buy |
3,746,086
+196,000
| +6% | +$4.39M | 1.2% | 26 |
|
|
2022
Q2 | $88M | Sell |
3,550,086
-26,400
| -0.7% | -$654K | 1.24% | 23 |
|
|
2022
Q1 | $139M | Sell |
3,576,486
-199,250
| -5% | -$7.72M | 1.61% | 15 |
|
|
2021
Q4 | $221M | Buy |
3,775,736
+537,700
| +17% | +$31.5M | 2.28% | 8 |
|
|
2021
Q3 | $192M | Buy |
3,238,036
+624,500
| +24% | +$37M | 1.95% | 10 |
|
|
2021
Q2 | $227M | Buy |
2,613,536
+404,200
| +18% | +$35.1M | 2.21% | 9 |
|
|
2021
Q1 | $182M | Buy |
2,209,336
+101,836
| +5% | +$8.4M | 1.93% | 11 |
|
|
2020
Q4 | $192M | Sell |
2,107,500
-110,000
| -5% | -$10M | 2.19% | 9 |
|
|
2020
Q3 | $88.6M | Buy |
2,217,500
+256,100
| +13% | +$10.2M | 1.22% | 23 |
|
|
2020
Q2 | $67.3M | Buy |
1,961,400
+398,200
| +25% | +$13.7M | 0.95% | 27 |
|
|
2020
Q1 | $34.7M | Buy |
1,563,200
+1,480,400
| +1,788% | +$32.9M | 0.67% | 42 |
|
|
2019
Q4 | $1.62M | Buy |
82,800
+22,700
| +38% | +$444K | 0.03% | 136 |
|
|
2019
Q3 | $933K | Buy |
60,100
+1,100
| +2% | +$17.1K | 0.02% | 147 |
|
|
2019
Q2 | $1.2M | Buy |
+59,000
| New | +$1.2M | 0.02% | 139 |
|